E-resources
Peer reviewed
Open access
-
Dulery, Remy; Reman, Oumedaly; Boumemdil, Ariane; Bouabdallah, Reda; Brice, Pauline; Gastinne, Thomas; Tabrizi, Reza; Quittet, Philippe; Huynh, Anne; Salles, Gilles; Monjanel, Helene; Stamatoullas, Aspasia; Bourhis, Jean-Henri; Bonmati, Caroline; Francois, Sylvie; Nguyen Quoc, Stephanie; Bay, Jacques Olivier; Cahn, Jean-Yves; Turlure, Pascal; Dauriac, Charles; Mohty, Mohamad; Peffault De Latour, Regis; Yakoub-Agha, Ibrahim
Blood, 12/2016, Volume: 128, Issue: 22Journal Article
Background Many patients with relapsed or refractory Hodgkin's lymphoma (HL) undergo high-dose chemotherapy (HDC) and autologous stem cell transplantation (auto-SCT). However, most large reports include patients treated in the 90's. We aimed to analyze the outcome of a HL patients treated in the last decade with HDC and auto-SCT in a large cohort study. Patients and methods In the setting of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy, we retrospectively analyzed 1987 consecutive adult patients (age < 65 years) with biopsy-proven HL who received a first auto-SCT between 2003 and 2014. Results Median age at auto-SCT was 33.7 years (range, 18-65) and 60% patients were male. Disease status at transplant was complete remission in 1040 patients (52%), partial response in 727 (37%) and progressive disease in 220 (11%). The main conditioning regimen was BEAM (Carmustine-Etoposide-Cytarabine-Melphalan, n=1497). At one month, cumulative incidence of neutrophil engraftment was 97.6% (95% CI 96.8-98.2), whereas cumulative incidence of death without engraftment was 0.2% (95% CI 0.07-0.5). After a median follow-up of 16.4 months (IQR, 4.4-47.2), 3-year overall survival (OS), disease-free survival (DFS), cumulative incidences of relapse (IR) and non-relapse mortality (NRM) were 80.4% (95% CI 78.1-82.9), 59% (95% CI 56.1-62), 35.9% (95% CI 33.1-38.7) and 5% (95% CI 3.9-6.4), respectively. There was no significant difference in terms of outcome between patients treated during the time period 2003-2008 and 2009-2014. 3-year OS and DFS were 70.5% and 43.7% in patients with progressive disease at transplant, 75% and 52.1% in patients in partial response, 87.2% and 67.8% in patients in complete remission (p<0.0001 and p<0.0001, respectively). Male had a decreased 3-year OS compared to female (HR 1.46, 95% CI: 1.15-1.84; p=0.002). Age ≥ 35 years was associated with a higher NRM (HR 1.67, 95% CI: 1.06-2.65; p=0.029) but a better PFS (HR 0.77, 95% CI: 0.65-0.91; p=0.002). Overall, patient age did not significantly influence OS (p=0.19). Primary refractory or multiple relapsed patients had a worse outcome than the others. A number of previous treatment lines ≥ 3 negatively influenced OS (HR 1.91, 95% CI: 1.42-2.58; p<0.0001), PFS (HR 2.03, 95% CI: 1.60-2.56; p<0.0001), IR (HR 1.90, 95% CI: 1.48-2.45; p<0.0001) and NRM (HR 3.17, 95% CI: 1.69-5.96; p=0.0003). Cumulative incidence of NRM reached 9% at 3 years in these patients. Finally, patients who relapsed after auto-SCT (n=494) had a 3-year OS of 52.8% (95% CI 47.7-58.3). Conclusion In conclusion, HDC followed by auto-SCT is highly efficient in relapsed HL patients. However, relapse occurs in over 40% of patients < 35 years old or with partial response at transplant and in over 50% of patients with progressive disease at transplant or ≥ 3 previous treatment lines. Additional data are being collected to better identify which high-risk patients could benefit from post-transplant immunotherapy or tandem auto-allo transplant. Brice:Roche: Honoraria; Bristol Myers-Squibb: Honoraria; Takeda Pharmaceuticals International Co.: Honoraria, Research Funding; Seattle Genetics: Research Funding; Gilead: Honoraria. Salles:Novartis: Consultancy, Honoraria; Amgen: Consultancy; Celgene: Consultancy, Honoraria; Gilead: Consultancy, Honoraria; Roche: Consultancy, Honoraria, Research Funding; Janssen: Honoraria. Peffault De Latour:PFIZER: Consultancy, Honoraria, Research Funding; NOVARTIS: Consultancy, Honoraria, Research Funding; ALEXION: Consultancy, Honoraria, Research Funding.
Author
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.